Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer.
AIMS: To investigate whether our practice of specialist review of all diagnostic biopsies was necessary to prevent misgrading of referred prostate cancer patients, and whether this misclassification, if any, would have resulted in misclassification of clinical risk grouping (Seattle Risk Grouping [SRG]) and subsequent treatment strategy and prognosis. MATERIALS AND METHODS: Important prognostic indicators for prostate cancer include the presenting prostate-specific antigen (PSA), clinical sta...Expand abstract
- Publisher copy:
- Clinical oncology (Royal College of Radiologists (Great Britain))
- Publication date:
- Source identifiers:
- Copyright date:
If you are the owner of this record, you can report an update to it here: Report update to this record